We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+11.27%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$15.6M
Cap. Flow
+$220M
Cap. Flow %
163.5%
Top 10 Hldgs %
31.52%
Holding
253
New
80
Increased
47
Reduced
36
Closed
74

Top Buys

1
HUM icon
Humana
HUM
+$4.21M
2
AMGN icon
Amgen
AMGN
+$3.4M
3
EHC icon
Encompass Health
EHC
+$3.34M
4
SLNO
Soleno Therapeutics
SLNO
+$3.29M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.9M

Top Sells

1
CNC icon
Centene
CNC
+$10.3M
2
UNH icon
UnitedHealth
UNH
+$4.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M
4
IBIT icon
iShares Bitcoin Trust
IBIT
+$3M
5
CON
Concentra Group Holdings
CON
+$2.39M

Sector Composition

1 Healthcare 51.79%
2 Financials 16.59%
3 Materials 5%
4 Technology 2.34%
5 Energy 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
226
PUT
Regeneron Pharmaceuticals
REGN
$70.9B
– –
-46
Closed -$112K
RLAY icon
227
CALL
Relay Therapeutics
RLAY
$4.34B
– –
-303
Closed -$9.85K
RYTM icon
228
Rhythm Pharmaceuticals
RYTM
$7.31B
– –
-11,501
Closed -$609K
SAGE
229
DELISTED
Sage Therapeutics
SAGE
– –
-42,216
Closed -$336K
FLNA
230
CALL
Filana Therapeutics
FLNA
$51.2M
– –
-690
Closed -$21
SGMT icon
231
Sagimet Biosciences
SGMT
$483M
– –
-10,597
Closed -$34.5K
SLNO
232
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-508
Closed -$855K
SLNO
233
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-533
Closed -$12.7K
SPY icon
234
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
– –
-55
Closed -$21.5K
SWTX
235
DELISTED
SpringWorks Therapeutics
SWTX
– –
-13,819
Closed -$610K
UBX
236
CALL
DELISTED
Unity Biotechnology
UBX
– –
-801
Closed -$6.06K
UBX
237
PUT
DELISTED
Unity Biotechnology
UBX
– –
-511
Closed -$15.5K
UNH icon
238
UnitedHealth
UNH
$387B
– –
-9,351
Closed -$4.9M
UWMC icon
239
UWM Holdings
UWMC
$685M
– –
-59,814
Closed -$327K
VERV
240
CALL
DELISTED
Verve Therapeutics
VERV
– –
-268
Closed -$13K
VKTX icon
241
CALL
Viking Therapeutics
VKTX
$4.31B
– –
-115
Closed -$3.03K
VLY icon
242
Valley National Bancorp
VLY
$8.28B
– –
-155,508
Closed -$1.38M
VNDA icon
243
Vanda Pharmaceuticals
VNDA
$327M
– –
-1,553
Closed -$7.13K
WAL icon
244
Western Alliance Bancorporation
WAL
$8.99B
– –
-8,970
Closed -$689K
WBS icon
245
Webster Financial
WBS
$12.3B
– –
-20,773
Closed -$1.07M
WFC icon
246
Wells Fargo
WFC
$265B
– –
-10,765
Closed -$773K
ZION icon
247
Zions Bancorporation
ZION
$10.6B
– –
-17,942
Closed -$895K
BTSG icon
248
BrightSpring Health Services
BTSG
$13.9B
– –
-87,872
Closed -$1.59M
GEV icon
249
GE Vernova
GEV
$284B
– –
-1,000
Closed -$305K
FSUN
250
FirstSun Capital Bancorp
FSUN
$1.66B
– –
-21,000
Closed -$759K
7 8 9
10
11

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Persistent Asset Partners held 253 positions worth $135M, up 13% from $119M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Persistent Asset Partners deployed $220M of net new capital in Q2 2025, opening 80 new positions and adding to 47 existing holdings. Its largest new stake was Amgen: 12,000 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 61% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $3.17M trimmed.

  • Persistent Asset Partners's largest Q2 2025 buy was Amgen: 12,000 shares worth $3.35M.
  • Persistent Asset Partners added most to Humana in Q2 2025, an estimated $4.21M increase.
  • Persistent Asset Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $3.17M.
  • Persistent Asset Partners fully exited Centene in Q2 2025, selling an estimated $10.3M.
  • Persistent Asset Partners's ten largest holdings make up 32% of its $135M portfolio in Q2 2025.
  • Persistent Asset Partners opened 80 new positions and closed 74 in Q2 2025.
  • Persistent Asset Partners's portfolio value rose 13% quarter-over-quarter to $135M.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.